06:03 , Apr 11, 2019 |  BioCentury  |  Finance

Syncona eyes a matching pair

Ten months after rounding out its gene therapy strategy with the last two investments in a five-company portfolio, Syncona has decided that two of its companies will fare better as a single entity. Syncona Ltd....
01:29 , Feb 1, 2019 |  BC Week In Review  |  Clinical News

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

OncoCyte Corp. (NYSE-A:OCX) said its DetermaVu liquid biopsy test detected lung cancer with sensitivity of 90% and specificity of 75% in the prospective R&D Validation study in 250 patient blood samples. OncoCyte said it will...
12:02 , Jan 29, 2019 |  BC Extra  |  Clinical News

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

OncoCyte Corp. (NYSE-A:OCX) said Tuesday its DetermaVu liquid biopsy test detected lung cancer with sensitivity of 90% and specificity of 75% in the prospective R&D Validation study in 250 patient blood samples. The news sent...
01:15 , Jan 25, 2019 |  BC Week In Review  |  Clinical News

Asterias' oligodendrocyte progenitor cell therapy improves motor function in SCI patients at 12 months

Asterias Biotherapeutics Inc. (NYSE-A:AST) reported 12-month data from the Phase I/IIa SCiStar trial to treat cervical spinal cord injury (SCI) showing that 21 of 22 patients (95%) who received 10 or 20 million cells of...
20:34 , Jan 18, 2019 |  BC Week In Review  |  Financial News

Juvenescence raises first tranche of $100M series B

Juvenescence Ltd. (Douglas, Isle of Man) raised $46 million on Jan. 16 in the first tranche of a $100 million series B round as it continues to mull an IPO late this year. Co-founder and...
23:59 , Jan 16, 2019 |  BC Extra  |  Financial News

Juvenescence raises first tranche of $100M series B

Juvenescence Ltd. (Douglas, Isle of Man) raised $46 million in the first tranche of a $100 million series B round as it continues to mull an IPO late this year. Co-founder and COO Alexander Pickett...
00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
21:52 , Sep 18, 2018 |  BC Extra  |  Company News

Management tracks: BioTime, Immune-Onc

Degenerative disease company BioTime Inc. (NYSE-A:BTX; Tel Aviv:BTX) named Brian Culley CEO, to replace co-CEOs Adi Mohanty and Michael West. Most recently, Culley was CEO of infectious disease company Artemis Therapeutics Inc. (OTCQB:ATMS). Immunotherapy company...
00:18 , Jun 16, 2018 |  BioCentury  |  Finance

Rejuvenating aging

Anti-aging company Juvenescence Ltd. is hoping to bring a total of 10 candidates from its portfolio companies and academic partnerships into the clinic over the next two years with its recent $50 million series A...
16:20 , Jun 15, 2018 |  BC Week In Review  |  Financial News

Juvenescence raises $50M series A

Juvenescence Ltd. (Douglas, Isle of Man) raised $50 million on June 11 in an oversubscribed series A round from founders, insiders, institutional investors and family offices. Juvenescence creates or invests in new companies to develop...